SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 643.85 |
| Enterprise Value ($M) | 398.90 |
| Book Value ($M) | 310.21 |
| Book Value / Share | 5.00 |
| Price / Book | 2.08 |
| NCAV ($M) | 284.43 |
| NCAV / Share | 4.59 |
| Price / NCAV | 2.26 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.14 |
| Return on Assets (ROA) | -0.19 |
| Return on Equity (ROE) | -0.20 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 29.71 |
| Current Ratio | 29.71 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 294.67 |
| Assets | 320.45 |
| Liabilities | 10.24 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -50.25 |
| Net Income | -38.96 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -42.28 |
| Cash from Investing | 65.14 |
| Cash from Financing | -0.30 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Fmr Llc | 4.80 | -20.71 | |
| 13G/A | Lynx1 Capital Management LP | 9.30 | 15.80 | |
| 13G/A | Ra Capital Management, L.p. | 12.90 | 19.68 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 21,038 | 60,971 | 34.50 | |
| 21,225 | 85,303 | 24.88 | |
| 19,681 | 77,778 | 25.30 | |
| 33,837 | 92,239 | 36.68 | |
| 38,800 | 132,816 | 29.21 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| FOLD – Amicus Therapeutics, Inc. | FULC – Fulcrum Therapeutics, Inc. |
| GANX – Gain Therapeutics, Inc. | HRMY – Harmony Biosciences Holdings, Inc. |
| HROW – Harrow, Inc. |
Financial data and stock pages provided by
Fintel.io